Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Piramal PharmaNSE:PPLPHARMA -0.56%50 3-Year ROIIC % is 16.09 as of Mar. 2026, which is 219% above its 10-year median of 5.05. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 50/100 and a GF Value™ of ₹186.01 (Fairly Valued). The stock has 6 warning signs investors should review. Among 946 Drug Manufacturers companies, Piramal Pharma ranks better than 67.76% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Piramal Pharma's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 16.09%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Piramal Pharma's 3-Year ROIIC % or its related term are showing as below:
NSE:PPLPHARMA's 3-Year ROIIC % is ranked better than 67.76% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs NSE:PPLPHARMA: 16.09
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Piramal Pharma 3-Year ROIIC % Related Terms
Piramal Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's 3-Year ROIIC % falls into.
Piramal Pharma's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 1549.1 (Mar. 2026) - -479.7 (Mar. 2023) )
/
( 139184.4 (Mar. 2026) - 126575.8 (Mar. 2023) )
=
2028.8
/
12608.6
=
16.09%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Piramal Pharma (NSE:PPLPHARMA) has a 3-Year ROIIC % of 16.09 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Piramal Pharma and its competitors. This is 219% above median its historical median of 5.05. According to the industry distribution chart, Piramal Pharma ranks #305 out of 946 companies in the Drug Manufacturers industry, placing it in the top 32.2%.
Is Piramal Pharma's 3-Year ROIIC % too high?
Piramal Pharma's current 3-Year ROIIC % of 16.09 is 219% above median its 10-year median of 5.05. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Piramal Pharma's value of 16.09 is 332.5% above this industry median. Based on the distribution chart, Piramal Pharma ranks #305 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Piramal Pharma has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #305 out of 946 companies for 3-Year ROIIC %. This puts Piramal Pharma in the upper half of its industry. The industry median 3-Year ROIIC % is 3.72. Piramal Pharma's value of 16.09 is 332.5% above this benchmark. While the company's 10-year median is 5.05 vs. the industry median of 3.72, Piramal Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current 3-Year ROIIC % of 16.09 is 332.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current 3-Year ROIIC % is 16.09, which is 219% above median its own 10-year median of 5.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹186.01, compared to a current price of ₹195.61 — trading 5.2% above its estimated fair value. The current 3-Year ROIIC % is 16.09, which is 219% above median its 10-year median of 5.05 and 332.5% above the Drug Manufacturers industry median of 3.72. Piramal Pharma's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current 3-Year ROIIC % is 16.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹195.61 is trading 5.2% above its estimated GF Value™ of ₹186.01.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
3-Year ROIIC %: 16.09 (219% above median its 10-year median of 5.05)
GF Value™: ₹186.01 vs. price of ₹195.61 (5.2% above fair value)
Industry Position: 332.5% above the Drug Manufacturers median (#305 of 946)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
50GF Score
Get the complete analysis for NSE:PPLPHARMA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
